Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02573272
Recruitment Status : Unknown
Verified September 2015 by Andalusian Network for Design and Translation of Advanced Therapies ( Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud ). Recruitment status was: Recruiting
First Posted : October 9, 2015
Last Update Posted : October 9, 2015
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Information provided by (Responsible Party):
Andalusian Network for Design and Translation of Advanced Therapies ( Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud )
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients diagnosed with focal epilepsy on stable treatment for the last two years
Patients over 18 years
patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests.
patients with stable and identifiable antiepileptic treatment during the last two years.
patients according to the investigator are able to provide clinical data necessary for the development of the study
Patients who signed informed consent
Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.